 If Cytokinetics Inc. CYTK , Financial can come anywhere close to achieving its lofty ambition of becoming the Vertex Pharmaceuticals Inc. VRTX , Financial of specialty cardiovascular drugs, shares of the San Francisco-based biopharma are a bargain at 45, even though that is pushing the companys 52-week high. 